Discounted Cash Flow (DCF) Analysis Unlevered

TRxADE HEALTH, Inc. (MEDS)

$0.47

+0.08 (+20.51%)
All numbers are in Millions, Currency in USD
Stock DCF: -21.37 | 0.47 | overvalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 2.933.837.4417.129.8915.1523.2135.5654.4883.46
Revenue (%)
EBITDA 0.450.07-0.14-2.40-5.15-1.55-2.37-3.63-5.56-8.52
EBITDA (%)
EBIT 0.450.07-0.23-2.51-5.29-1.71-2.62-4.02-6.16-9.43
EBIT (%)
Depreciation --0.090.100.140.170.250.390.600.91
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash 0.180.872.875.923.124.056.219.5114.5722.32
Total Cash (%)
Account Receivables 0.320.430.791.890.981.632.503.835.868.98
Account Receivables (%)
Inventories -0.080.061.260.060.410.620.961.472.25
Inventories (%)
Accounts Payable 0.110.400.330.260.480.751.161.772.714.16
Accounts Payable (%)
Capital Expenditure --0.02-0.08-0.04-0.02-0.07-0.11-0.17-0.26-0.41
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.47
Beta 1.176
Diluted Shares Outstanding 8.14
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 1.89%
Risk-Free Rate
Market Risk Premium
Cost of Equity 9.096
Total Debt 1.25
Total Equity 3.82
Total Capital 5.07
Debt Weighting 24.61
Equity Weighting 75.39
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 2.933.837.4417.129.8915.1523.2135.5654.4883.46
EBITDA 0.450.07-0.14-2.40-5.15-1.55-2.37-3.63-5.56-8.52
EBIT 0.450.07-0.23-2.51-5.29-1.71-2.62-4.02-6.16-9.43
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT 0.450.07-0.23-2.51-5.29-1.71-2.62-4.02-6.16-9.43
Depreciation --0.090.100.140.170.250.390.600.91
Accounts Receivable --0.11-0.36-1.100.91-0.65-0.87-1.33-2.04-3.12
Inventories --0.02-1.201.20-0.35-0.22-0.33-0.51-0.78
Accounts Payable -0.29-0.07-0.080.220.280.400.610.941.44
Capital Expenditure --0.02-0.08-0.04-0.02-0.07-0.11-0.17-0.26-0.41
UFCF 0.450.23-0.62-4.82-2.84-2.35-3.17-4.85-7.43-11.38
WACC
PV UFCF -2.19-2.75-3.92-5.60-7.99
SUM PV UFCF -22.45

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 7.32
Free cash flow (t + 1) -11.61
Terminal Value -218.20
Present Value of Terminal Value -153.27

Intrinsic Value

Enterprise Value -175.72
Net Debt -1.87
Equity Value -173.84
Shares Outstanding 8.14
Equity Value Per Share -21.37